“Our numbers are muted this quarter, but we expect a strong bounce back Q2 onwards. Our US sales took a significant dip as we took several ...

Investors looking for safer bets and craving for returns in an uncertain market are taking shelter in these defensive bets.

The Nifty Pharma index was trading 0.51 per cent down at 11223.75.

The crucial lower supports to watch are around the 11,000-10,950 zone for the next few sessions, before the index shows any upside bounce f...

The sector has its own battles to fight – which are more regulatory, global and endemic in nature.

The domestic business grew 6 per cent, showing the impact of a high base effect.

The reshuffle is likely to make the index marginally cheaper.

Add Lupin Ltd. at a price target of Rs 815.

As of September, the company had about $152 million in cash, and in its most recent earnings conference call said it had about $810 million...

There are enough stocks that have managed to withstand this onslaught. A study of performance of the CNX 500 index shows over 200 stocks ha...

After a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.

Besides, Adani Power will be dropped from the BSE 100 index while various changes have been made to a host of other BSE indices as well.

Lupin posted its worst quarterly performance with a drop in growth in key markets like US and Japan, resulting in flat revenues and a 300-b...

The brokerage downgraded its rating on Sun to ‘underperform’, and on Lupin, Cipla and Cadila to ‘neutral’ from ‘buy’.

Pharma cos including Sun Pharma, Lupin, Cadila Healthcare and Cipla weakened on Thursday after BofA-ML's downgrade.

Most of the analysts are bullish on Lupin as the weak rupee provides much support to the stock and consistent performance in the past auger...

State-run steel giant SAIL and Vedanta group firm Sterlite Industries are being moved out of the National Stock Exchange's benchmark index ...